ByronJHoogwerfMD

PubMed

• 164 citations
  Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
  Michaela Diamant, Michael A. Nauck, Rimma M. Shaginian, James Malone, Simon Cleall
  Diabetes Care. 2014-10-01
• 338 citations
  Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
  Rodica Pop-Busui, Gregory W. Evans, Hertzel C. Gerstein, Vivian Fonseca, Jerome L. Fleg
  Diabetes Care. 2010-07-01
• 20 citations
  Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
  Julia A Gaebler, Gerardo Soto-Campos, Peter Alperin, Marc Cohen, Amy Blickensderfer
  Vascular Health and Risk Management. 2012-04-23

Journal Articles

• Risk Factors for 30-Day Readmission Following Hypoglycemia-Related Emergency Room and Inpatient Admissions  
  Emons MF, Bae JP, Hoogwerf BJ, Kindermann SL, Taylor RJ, Nathanson BH, BMJ Open Diab Res Care, 1/1/2016
• Major Adverse Cardiovascular Events with Basal Insulin Peglispro versus Comparator Insulins in Patients with Type 1 or Type 2 Diabetes: a meta-analysis  
  Hoogwerf BJ, Lincoff AM, Rodriguez A, Chen L, Qu Y., Cardiovascular Diabetology., 1/1/2016
• Perspectives on some controversies in cardiovascular disease risk assessment in the pharmaceutical development of glucose lowering medications  
  Hoogwerf, BJ, Manner, DH, Fu, H, Moscarelli, E, Gaydos, BL, Heine, R, Diabetes Care, 1/1/2016
• Similar HbA1c Reduction and Hypoglycaemia with Variable- Vs Fixed-Time Dosing of Basal Insulin Peglispro (BIL) in Type 1 Diabetes: IMAGINE 7 Study  
  Garg S, MD, Selam J-L, MD, Bhargava A, Schloot N, Luo J, Zhang Q, Jacobson JG, Hoogwerf BJ., Diabetes Obes Metab, 1/1/2016
• Lipid Changes During Basal Insulin Peglispro, Insulin Glargine, or NPH Treatment in 6 IMAGINE Trials  
  Ginsberg H, Cariou B, Orchard TO, Chen L, Luo J, Bastyr III EJ, Bue-Valleskey J, Chang AM, Ivanyi T, Jacober SJ, Hoogwerf BJ., Diabetes Obes Metab, 1/1/2016
• Obesity and Glycemic Control in Patients with Diabetes Mellitus: Analysis of Physician Electronic Health Records in the US from 2009-2011  
  Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ, J of Diabetes and it Complications, 1/1/2015
• A Profile of the Intersection among Science, the Fine Arts and Education  
  Hoogwerf, BJ, Kendall, DK, Seaquist, ER Frederick C. Goetz, Diabetes Care, 1/1/2014
• Effects of Exenatide on Kidney Function, Adverse Events and Clinical Endpoints of Kidney Disease in Type 2 Diabetes  
  Tuttle KR, Heilmann C, Hoogwerf BJ, Brown C, Anderson PW., AJKD (research letter)., 1/1/2013
• Metabolic outcomes of matched patient populations initiating exenatide BID vs insulin glargine in an ambulatory care setting  
  Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, et al., Diabetes Obes Metab., 1/1/2012
• Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications  
  Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J., Postgrad Med., 1/1/2012
• Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide  
  Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J, Endocr Pract., 1/1/2012
• Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy  
  Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB., Int J Clin Pract, 1/1/2012
• Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other g...  
  Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al., Diabetes Care., 1/1/2011
• Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy  
  Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R., J Med Econ., 1/1/2011
• Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes  
  Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L., Cardiovasc Diabetol., 1/1/2011
• Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study  
  Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, et al., Cardiovasc Diabetol, 1/1/2010
• Renin-angiotensin system blockade and cardiovascular and renal protection  
  Hoogwerf BJ., Am J Cardiol., 1/1/2010
• The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study  
  Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ., Obesity (Silver Spring)., 1/1/2010
• Association of SF-36 with coronary artery disease risk factors and mortality: a PreCIS study  
  Zhang JP, Pozuelo L, Brennan DM, Hoar B, Hoogwerf BJ., Prev Cardiol., 1/1/2010
• Clinical utility of waist circumference in predicting all-cause mortality in a preventive cardiology clinic population: a PreCIS Database Study  
  Bajaj HS, Brennan DM, Hoogwerf BJ, Doshi KB, Kashyap SR., Obesity (Silver Spring)., 1/1/2009
• All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study  
  Doshi KB, Kashyap SR, Brennan DM, Hoar BM, Cho L, Hoogwerf BJ., Diabetes Obes Metab., 1/1/2009
• Cleveland Clinic cardiovascular intensive care unit insulin conversion protocol  
  Olansky L, Sam S, Lober C, Yared JP, Hoogwerf B, J Diabetes Sci Technol., 1/1/2009
• Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study  
  Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL., J Womens Health (Larchmt)., 1/1/2008
• Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreC...  
  Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ., Arthritis Rheum., 1/1/2008
• Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes  
  Nielsen LL, Okerson T, Holcombe J, Hoogwerf B., J Diabetes Sci Technol., 1/1/2008
• Join now to see all

Books/Book Chapters

• Rapid Review: USMLE Step 3 
  Chapter: Endocrinology 
  Page 248.0 - 283.0Newton, M, Hoogwerf, B.Editors: D.D.K. Rolston & C. Neilsen.Mosby Elsevier, Philadelphia2008
• Preventive Cardiology: Insights into the Prevention and Treatment of Cardiovascular Disease 
  Chapter: Diabetes Mellitus, Hyperinsulinemia and Coronary Artery Disease. 
  Page 113.0 - 144.0Hoogwerf, BJ.Editors: J M Foody.Humana Press, Totowa, NJEdition Seco,2006
• Inflammatory Diseases of Blood Vessels 
  Chapter: Dyslipidemia in Rheumatic Disorders 
  Page 767.0 - 780.0Hoogwerf, BJ, Danese R, Villa-Forte A.Editors: G. Hoffman & C. Weyand.Marcel Dekker, Inc., New York2001
• Preventive Cardiology: Strategies for Prevention and Treatment of Coronary Artery Disease 
  Chapter: Diabetes Mellitus, Hyperinsulinemia and Coronary Artery Disease 
  Page 177.0 - 142.0Hoogwerf BJEditors: J M Foody.Humana Press, Totowa, NJ2000
• Peripheral Vascular Diseases 
  Chapter: Diagnosis and Treatment of Lipid Disturbances 
  Page 166.0 - 188.0Olin JW, Cressman MD, Hoogwerf BJ, Weinstein CEEditors: J Young et al..Mosby, St. LouisEdition Seco,1996
• The High Risk Patient: Management of the Critically Ill 
  Chapter: The Diabetic Patient 
  Hoogwerf BJEditors: Edward Sivak, Tom Higgins and Adam Seiver.Williams and Wilkins, Meda, PA1995
• Clinical Cardiac Rehabilitation: a Cardiologists Guide 
  Chapter: Cardiac rehabilitation in the diabetic patient 
  Hoogwerf BJEditors: Pashkow FJ and Dafoe WA.Williams & Wilkins, Baltimore, Maryland1993
• Textbook of Peripheral Vascular Disease 
  Chapter: The Diagnosis and Treatment of Lipid Disturbances 
  Olin J, Cressman M, Hoogwerf BJ, Weinstein CEditors: Jess Young, et al..Edition 161.,1991
• Lipids and Women's Health 
  Chapter: Diabetes Mellitus in Women 
  Hoogwerf BJEditors: G. Redmond.Springer Verlag1990
• Lipids and Women's Health 
  Chapter: Dietary Treatment of Lipids and Lipoprotein Disorders 
  Hoogwerf BJEditors: G. Redmond.Springer VerlagEdition 160.,1990
• Join now to see all